U.S. markets open in 1 hour 8 minutes
  • S&P Futures

    3,819.50
    -19.50 (-0.51%)
     
  • Dow Futures

    31,437.00
    -28.00 (-0.09%)
     
  • Nasdaq Futures

    12,511.25
    -152.50 (-1.20%)
     
  • Russell 2000 Futures

    2,187.20
    -2.50 (-0.11%)
     
  • Crude Oil

    65.68
    -0.41 (-0.62%)
     
  • Gold

    1,684.40
    -14.10 (-0.83%)
     
  • Silver

    25.05
    -0.24 (-0.94%)
     
  • EUR/USD

    1.1869
    -0.0055 (-0.46%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    27.25
    -1.32 (-4.62%)
     
  • GBP/USD

    1.3848
    +0.0020 (+0.14%)
     
  • USD/JPY

    108.5790
    +0.1970 (+0.18%)
     
  • BTC-USD

    50,489.96
    -243.00 (-0.48%)
     
  • CMC Crypto 200

    1,021.03
    +77.86 (+8.26%)
     
  • FTSE 100

    6,621.77
    -8.75 (-0.13%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

Exact Sciences: 4Q Earnings Snapshot

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported a fourth-quarter loss of $436.8 million, after reporting a profit in the same period a year earlier.

The Madison, Wisconsin-based company said it had a loss of $2.79 per share. Losses, adjusted for costs related to mergers and acquisitions, came to 9 cents per share.

The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share.

The molecular diagnostics company posted revenue of $466.3 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $466 million.

For the year, the company reported that its loss widened to $848.5 million, or $5.61 per share. Revenue was reported as $1.49 billion.

Exact Sciences shares have increased 16% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $154.28, an increase of 63% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EXAS at https://www.zacks.com/ap/EXAS